Ambrosia Medical is offering willing customers blood transfusions from young donors. It’s the first of its kind in the medical field since clinical trials were done last year. It sounds like something pretty unnecessary and only for vanity purposes. Have they found any real benefit from receiving blood from young people?
Reversing the sands of time
The startup was founded by Jesse Karmazin, a Stanford University graduate. The company aims to open its first clinic in New York City this year.
Although young blood transfusions aren’t a new practice, the results from the first clinical trials were “really positive”. The participation fee was $8,000 to enter into the program. People aged 35 to 90 received 1.5litres of blood from young donors aged 16-25.
Biomarkers were taken before and after the experiment which indicates better or poorer general health and the likelihood of getting diseases. The actual results haven’t been published as of yet, so we don’t know exactly how beneficial it is. Although participants did say their memory and sleep were better after the transfusions.
However, 100 people have enquired about the service which has proved promising.
It is legal?
There is nothing illegal about what they are doing. Blood transfusions are approved by federal regulators and Ambrosia Medical aren’t adding any illicit substances or non-FDA approved materials.
The idea is that young blood transfusions slow the ageing process by invigorating organs and promoting growth.
Studies on mice have shown promise. Experiments showed an improved circulatory system when older mice received blood from younger rodents. However, there’s no concrete evidence the same benefits apply to humans.
Still no concrete evidence
Ranveer Gathwala, a UC Berkeley stem-cell researcher, has remarked that on the surface, young blood transfusions seem to be rejuvenating.
“The effects of young blood on old tissue seems to be rejuvenating; however, there is no concrete evidence that young blood is what is causing the change in results. It may very well be the dilution of old blood”.
Safety doesn’t seem to be an issue, as no one suffered any negative side effects.
But not everyone is happy with the service being offered. Tony Wyss-Coray, a Stanford University neuroscientist, says that there isn’t any discernible difference between those who have done young blood transfusions and normal ones.
“There’s just no clinical evidence [that the treatment will be beneficial], and you’re basically abusing people’s trust and the public excitement around this”, he told Science magazine. Dr Wyss-Coray led a similar experiment on mice in 2014.
However, the negativity is not stopping Karmazin from proceeding with his plans for expansion. “I’m really happy with the results we’re seeing,” he said.
Could this be the fountain of youth everyone is looking for? And if it is, would you pay $8,000 to be younger?
Read more articles below: